[go: up one dir, main page]

Ikpa et al., 2015 - Google Patents

In vitro studies on degradation of gamma-l-glutamyl-l-cysteine and gamma-l-glutamyl-d-cysteine in blood: Implications for treatment of stroke

Ikpa et al., 2015

Document ID
13787114251909544423
Author
Ikpa N
Forman R
Garchow K
Sukowski E
Peterson D
Publication year
Publication venue
American Journal of Therapeutics

External Links

Snippet

Abstract Treatment for ischemic stroke involves a thrombolytic agent to re-establish blood flow in the brain. However, delayed reperfusion may cause injury to brain capillaries. Previous studies indicate that the antioxidant gamma-L-glutamyl-L-cysteine (γ-Glu-Cys) …
Continue reading at journals.lww.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Similar Documents

Publication Publication Date Title
D'Alessandro et al. Red blood cell metabolic responses to refrigerated storage, rejuvenation, and frozen storage
D'Alessandro et al. Red blood cell storage in additive solution‐7 preserves energy and redox metabolism: a metabolomics approach
DʼAlessandro et al. Hypoxic storage of red blood cells improves metabolism and post‐transfusion recovery
Lyons et al. Cysteine metabolism and whole blood glutathione synthesis in septic pediatric patients
Baker et al. Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells
Brustovetsky et al. A large Ca2+-dependent channel formed by recombinant ADP/ATP carrier from Neurospora crassa resembles the mitochondrial permeability transition pore
Jones Radical-free biology of oxidative stress
Harper et al. Peroxiredoxin-2 recycling is inhibited during erythrocyte storage
Dumont et al. CO2‐dependent metabolic modulation in red blood cells stored under anaerobic conditions
Murata et al. Nitrite reduces ischemia/reperfusion-induced muscle damage and improves survival rates in rat crush injury model
Genova et al. A critical appraisal of the role of respiratory supercomplexes in mitochondria
Yew et al. Erythrocytes encapsulated with phenylalanine hydroxylase exhibit improved pharmacokinetics and lowered plasma phenylalanine levels in normal mice
Tu et al. Chemical transport knockout for oxidized vitamin C, dehydroascorbic acid, reveals its functions in vivo
Ginsberg Life after cerovive: a personal perspective on ischemic neuroprotection in the post–NXY-059 era
Wijermars et al. Succinate accumulation and ischemia–reperfusion injury: of mice but not men, a study in renal ischemia–reperfusion
Rafikova et al. Control of plasma nitric oxide bioactivity by perfluorocarbons: physiological mechanisms and clinical implications
Zhang et al. Targeting mTORC2/HDAC3 inhibits stemness of liver cancer cells against glutamine starvation
Meininger et al. [24] Regulation of endothelial cell proliferation by nitric oxide
Wang et al. Carbonic anhydrase II does not regulate nitrite‐dependent nitric oxide formation and vasodilation
Gehrke et al. Metabolic impact of red blood cell exchange with rejuvenated red blood cells in sickle cell patients
Leitch et al. The methylimidazolium ionic liquid M8OI is detectable in human sera and is subject to biliary excretion in perfused human liver
Lee et al. Methylglyoxal in cells elicits a negative feedback loop entailing transglutaminase 2 and glyoxalase 1
Ruiz et al. Adaptive responses of mitochondria to mild copper deprivation involve changes in morphology, OXPHOS remodeling and bioenergetics
Cilenti et al. Regulation of metabolism by mitochondrial MUL1 E3 ubiquitin ligase
EP4339295A2 (en) Storage device, system and method for determining the metabolic state of red blood cells and platelets